CEROX1

Across TCGA pan-cancer cohorts, CEROX1 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of CEROX1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where CEROX1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CEROX1 is over-expressed in tumor, although a few such as BLCA and BRCA show the opposite, repressed pattern.

THCA, BLCA, and KIRP are the cancer types where CEROX1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CEROX1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	II,III,IV	+1.985	<.001	10	view →
BLCA	All	III,IV	−0.544	<.001	8	view →
KIRP	All	III,IV	+2.232	<.001	7	view →
BRCA	Female	II,III,IV	−1.655	<.001	6	view →
CHOL	Female	All	+0.966	.005	5	view →
LIHC	All	All	+0.194	<.001	5	view →
STAD	All	All	+0.613	.017	4	view →
COAD	All	II,III,IV	+0.600	.011	4	view →
HNSC	All	II,III,IV	−0.532	.003	4	view →
UCEC	All	All	−0.654	<.001	2	view →
LUAD	Female	All	+0.367	.006	2	view →
PRAD	All	All	+0.246	.037	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

CEROX1–THCA

Open the THCA breakdown →